Compare NCA & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NCA | VCRE |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.0M | 271.7M |
| IPO Year | 1995 | 2026 |
| Metric | NCA | VCRE |
|---|---|---|
| Price | $8.46 | $9.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $29.97 |
| AVG Volume (30 Days) | ★ 187.4K | 21.5K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $101.29 |
| Revenue Next Year | N/A | $481.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.12 | $7.88 |
| 52 Week High | $9.80 | $14.01 |
| Indicator | NCA | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 51.04 |
| Support Level | $8.20 | $8.70 |
| Resistance Level | $8.62 | $11.88 |
| Average True Range (ATR) | 0.15 | 0.54 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 69.23 | 44.12 |
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.